233
Participants
Start Date
October 13, 2020
Primary Completion Date
May 3, 2022
Study Completion Date
May 3, 2022
DS102
DS102 Epeleuton capsules
Placebo
Placebo capsules
US Site 2, Albany
US Site 3, Yardley
US Site 1, Wyomissing
US Site 17, Winchester
US Site 34, Raleigh
US Site 26, Rocky Mount
US Site 28, Salisbury
US Site 11, Morehead City
US Site 25, Hickory
US Site 27, Wilmington
US Site 32, Statesville
US Site 15, Adairsville
US Site 12, Jackson
US Site 35, Ames
US Site 5, Little Rock
US Site 22, Edmond
US Site 7, Dallas
US Site 8, Fort Worth
US Site 14, Fort Worth
US Site 31, North Richland Hills
US Site 10, Waco
US Site 24, Houston
US Site 30, Houston
US Site 6, Houston
US Site 33, Houston
US Site 29, Missouri City
US Site 19, Los Angeles
US Site 18, Huntington Park
US Site 23, Cerritos
US Site 20, Panorama City
US Site 21, Santa Ana
US Site 13, Santa Ana
Georgia Site 1, Batumi
Georgia Site 2, Kutaisi
Georgia Site 3, Kutaisi
Georgia Site 4, Tbilisi
Germany Site 7, Dresden
Germany Site 3, Hamburg
Germany Site 1, Heidelberg
Germany Site 5, Lübeck
Israel Site 9, Herzliya
Israel Site 1, Holon
Israel Site 5, Jerusalem
Israel Site 6, Jerusalem
Israel Site 4, Nahariya
Israel Site 8, Sakhnin
Israel Site 2, Tel Aviv
Israel Site 3, Tel Aviv
Latvia Site 4, Ogre
Latvia Site 1, Riga
Latvia Site 2, Riga
Latvia Site 3, Riga
Switzerland Site 3, Lausanne
Switzerland Site 4, Lucerne
Switzerland Site 2, Olten
Switzerland Site 1, Sankt Gallen
Lead Sponsor
Afimmune
INDUSTRY